The EU parliament offers a Q&A page where you can get updates and ask questions regarding the disruption of medical supply chains during the COVID-19 pandemic and measures taken by all EU countries. Up to 90% of active ingredients in medicines are produced in China and India. This has made the EU national health systems vulnerable during the COVID pandemic. Not only is the EU reliant on receiving the active ingredients from abroad under coronavirus restrictions but the situation is exacerbated by some member states restricting the intra-community movement of pharmaceuticals. This may lead to shortages and disruption of the medical supply chain.
EU Parliamentary Q&A: Disruption of medical supply chains in the EU due to COVID-19 and unilateral national measures